Therapeutic standards for ovarian cancer;Standards in der therapie des ovarialkarzinoms

Pathologe

Volumn 28, Issue 3, 2007, Pages 222-228

  Pfisterer, J ^a,c   Du Bois, A ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Chemotherapy; Ovarian Cancer; Surgical staging; Therapy of recurrent disease

Indexed keywords

CARBOPLATIN; PACLITAXEL; TAXANE DERIVATIVE;

ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL PRACTICE; HUMAN; OVARY CANCER; PRACTICE GUIDELINE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; RECURRENCE;

EID: 34250155664     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-007-0907-9     Document Type: Article

References (20)

1. Benedetti Panici P, Maggioni A, Hacker N et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97: 560-566
2. Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-1259
3. Colombo N, Guthrie D, Chiari S et al. (2003) International Collaborative Ovarian Neoplasm (ICON) collaborators: International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95: 125-132
4. nd-line- Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998. Geburtsh Frauenheilk 60: 41-58
5. Du Bois A, Lück HJ, Meier W et al. (2003) A randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329
6. Du Bois A, Rochon J, Lamparter C, Pfisterer J (2005) Ovarialkarzinom - Versorgungsstruktur und -qualität in Deutschland 2001-2004. Frauenarzt 46: 560-567
7. Du Bois A, Quinn M, Thigpen T et al. (2005) 2004 Consensus statements on the management of ovarian cancer - final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16 Suppl 8: viii7-viii12
8. Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88: 144-153
9. Harter P, Breitbach GP, Tanner B et al. (2005) Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR). J Clin Oncol 23 (16S): abstr 5004
10. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10: 513-514
11. McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
12. Muggia FM, Braly PS, Brady MF et al. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 18: 106-115
13. Ozols RF, Bundy BN, Greer BE et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. A Gynecologic Oncology Group Study. J Clin Oncol 21: 3194-3200
14. Pfisterer J, Plante M, Vergote I et al. (2004) Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a gynecologic cancer intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 22 (14S): abstr 5005
15. Piccart MJ, Bertelsen K, James K et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer. J Natl Cancer Inst 92: 699-708
16. Sakurai S, Shimizu Y, Utsugi K et al. (2002) Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma. Proc Am Soc Clin Oncol 21: abstr 801
17. The ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 361: 2099-2106
18. The International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515
19. Trimbos JB (2000) Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer 10 (S1): 8-11
20. Trimbos JB, Vergote I, Bolis G et al., EORTC-ACTION collaborators, European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113-125